AMS Onsite Partners with Arkstone to Further Reduce Antibiotic Resistance, Improve Health Outcomes
AMS Onsite, the leading infection control and prevention (ICP) practice for America's long-term care facilities, today announced a partnership with Arkstone Medical Solutions, a pioneer in infectious disease treatment guidance. The integration allows AMS Onsite to leverage Arkstone’s proprietary report and targeted treatment recommendations, further reducing antibiotic resistance and infections and improving health outcomes for residents in long-term care and skilled nursing facilities.
Arkstone Incorporates Patient Allergies Into Its Already Powerful Analysis Toolkit
Arkstone's OneChoice technology automatically analyzes many factors like specimen source, organisms and genes detected, patient age and gender, and diagnosis, to arrive at a targeted precision-guided treatment recommendation. By incorporating which antibiotics the patient may be allergic to, the recommendations are now even more tailored to the specific patient's needs.
Arkstone Launches Specialized COVID-19 Reports with Latest Treatments Guidelines
The new COVID-19 Pandemic Alert section incorporates infection statistic information from Johns Hopkins University, specific to the location of the patient, to help keep providers informed of potential increases in infection rates. While no treatment or vaccine is yet available, the Arkstone Report continues to assist providers in making informed care decisions by including the latest treatment information at the time of the lab test.